Alexion Pharmaceuticals reports that the European Commission has approved ULTOMIRIS® (ravulizumab) for the treatment of adults and children with a body weight of 10 kg or above with atypical hemolytic uremic syndrome who are complement inhibitor treatment-naïve or have received SOLIRIS® (eculizumab) for at least three months and have evidence of response to eculizumab.